{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:41:37Z","timestamp":1790901697813,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012834","name":"Gifu University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012834","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01591-y","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:13:19Z","timestamp":1789121599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab"],"prefix":"10.1007","volume":"57","author":[{"given":"Hironori","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunami","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Yasufuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakana","family":"Chikaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kitahora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Tomida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"1591_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.003","author":"YY Janjigian","year":"2026","unstructured":"Janjigian YY, Shitara K, Ajani JA, Shen L, Garrido M, Gallardo C, et al. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.02.003.","journal-title":"Ann Oncol"},{"key":"1591_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/s1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395. https:\/\/doi.org\/10.1016\/s1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"key":"1591_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/01635581.2025.2492126","volume":"77","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhang Y, Tang X, Zhang S, Man C, Gong D, et al. The prevalence and prognostic impact of cancer cachexia on overall survival in patients with gastrointestinal cancer: a meta-analysis. Nutr Cancer. 2025;77:590\u20139. https:\/\/doi.org\/10.1080\/01635581.2025.2492126.","journal-title":"Nutr Cancer"},{"key":"1591_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/01635581.2015.1073753","volume":"67","author":"L Sun","year":"2015","unstructured":"Sun L, Quan XQ, Yu S. An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr Cancer. 2015;67:1056\u201362. https:\/\/doi.org\/10.1080\/01635581.2015.1073753.","journal-title":"Nutr Cancer"},{"key":"1591_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00595-023-02721-w","volume":"54","author":"T Matsunaga","year":"2024","unstructured":"Matsunaga T, Satio H, Sakano Y, Makinoya M, Shimizu S, Shishido Y, et al. Prognostic significance of the cachexia index in patients with unresectable advanced gastric cancer receiving palliative chemotherapy: a retrospective single-center study. Surg Today. 2024;54:231\u20139. https:\/\/doi.org\/10.1007\/s00595-023-02721-w.","journal-title":"Surg Today"},{"key":"1591_CR7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1007\/s00595-022-02493-9","volume":"52","author":"T Namikawa","year":"2022","unstructured":"Namikawa T, Marui A, Yokota K, Fujieda Y, Munekage M, Uemura S, et al. Frequency and prognostic impact of cachexia during drug treatment for unresectable advanced gastric cancer patients. Surg Today. 2022;52:1560\u20137. https:\/\/doi.org\/10.1007\/s00595-022-02493-9.","journal-title":"Surg Today"},{"key":"1591_CR8","first-page":"15222","volume":"8","author":"X Zhang","year":"2015","unstructured":"Zhang X, Chen X, Wu T, Zhang Y, Yan K, Sun X. Modified Glasgow prognostic score as a prognostic factor in gastric cancer patients: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:15222\u20139. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4658896\/.","journal-title":"Int J Clin Exp Med"},{"key":"1591_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00384-025-04962-2","volume":"40","author":"H Fujii","year":"2025","unstructured":"Fujii H, Kani M, Watanabe D, Miura Y, Chikaishi W, Tajima JY, et al. Cancer cachexia onset and survival outcomes in metastatic colorectal cancer: comparative assessment of the Asian Working Group for Cachexia and the European Palliative Care Research Collaborative criteria, and utility of modified Glasgow Prognostic Score. Int J Colorectal Dis. 2025;40:164. https:\/\/doi.org\/10.1007\/s00384-025-04962-2.","journal-title":"Int J Colorectal Dis"},{"key":"1591_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.annonc.2022.03.274","volume":"33","author":"UT Hacker","year":"2022","unstructured":"Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannova R, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol. 2022;33:685\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.274.","journal-title":"Ann Oncol"},{"key":"1591_CR11","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.21873\/anticanres.14734","volume":"40","author":"H Fujii","year":"2020","unstructured":"Fujii H, Makiyama A, Iihara H, Okumura N, Yamamoto S, Imai T, et al. Cancer cachexia reduces the efficacy of nivolumab treatment in patients with advanced gastric cancer. Anticancer Res. 2020;40:7067\u201375. https:\/\/doi.org\/10.21873\/anticanres.14734.","journal-title":"Anticancer Res"},{"key":"1591_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3892\/mco.2022.2524","volume":"16","author":"H Fujii","year":"2022","unstructured":"Fujii H, Araki A, Iihara H, Kaito D, Hirose C, Kinomura M, et al. Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer. Mol Clin Oncol. 2022;16:91. https:\/\/doi.org\/10.3892\/mco.2022.2524.","journal-title":"Mol Clin Oncol"},{"key":"1591_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/cej.0000000000000946","volume":"34","author":"H Zhang","year":"2025","unstructured":"Zhang H, Tang X, Zhang J, Jiang D, Gong D, Fan Y. Association between weight loss and survival outcomes in patients with gastric cancer: a meta-analysis. Eur J Cancer Prev. 2025;34:550\u20138. https:\/\/doi.org\/10.1097\/cej.0000000000000946.","journal-title":"Eur J Cancer Prev"},{"key":"1591_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236445","volume":"15","author":"MR Kim","year":"2020","unstructured":"Kim MR, Kim AS, Choi HI, Jung JH, Park JY, Ko HJ. Inflammatory markers for predicting overall survival in gastric cancer patients: a systematic review and meta-analysis. PLoS One. 2020;15:e0236445. https:\/\/doi.org\/10.1371\/journal.pone.0236445.","journal-title":"PLoS One"},{"key":"1591_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s11605-010-1162-6","volume":"14","author":"AB Crumley","year":"2010","unstructured":"Crumley AB, Stuart RC, McKernan M, Going JJ, Shearer CJ, McMillan DC. Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg. 2010;14:781\u20137. https:\/\/doi.org\/10.1007\/s11605-010-1162-6.","journal-title":"J Gastrointest Surg"},{"key":"1591_CR16","doi-asserted-by":"publisher","first-page":"100177","DOI":"10.1016\/j.esmogo.2025.100177","volume":"8","author":"S Udagawa","year":"2025","unstructured":"Udagawa S, Ooki A, Osumi H, Yoshino K, Tamba M, Shimozaki K, et al. The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy. ESMO Gastrointest Oncol. 2025;8:100177. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100177.","journal-title":"ESMO Gastrointest Oncol"},{"key":"1591_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534\u201340. https:\/\/doi.org\/10.1016\/j.ctrv.2012.08.003.","journal-title":"Cancer Treat Rev"},{"key":"1591_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer. 2023;129:1212\u201324. https:\/\/doi.org\/10.1038\/s41416-023-02361-4.","journal-title":"Br J Cancer"},{"key":"1591_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen J, Melero I, Fridman WH. Growth\/Differentiation Factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:951. https:\/\/doi.org\/10.3389\/fimmu.2020.00951.","journal-title":"Front Immunol"},{"key":"1591_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39817-3","volume":"14","author":"M Haake","year":"2023","unstructured":"Haake M, Haack B, Sch\u00e4fer T, Harter PN, Mattavelli G, Eiring P, et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat Commun. 2023;14:4253. https:\/\/doi.org\/10.1038\/s41467-023-39817-3.","journal-title":"Nat Commun"},{"key":"1591_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","volume":"637","author":"I Melero","year":"2025","unstructured":"Melero I, de Miguel Luken M, de Velasco G, Garralda E, Mart\u00edn-Liberal J, Joerger M, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025;637:1218\u201327. https:\/\/doi.org\/10.1038\/s41586-024-08305-z.","journal-title":"Nature"},{"key":"1591_CR22","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/jcsm.13323","volume":"14","author":"H Arai","year":"2023","unstructured":"Arai H, Maeda K, Wakabayashi H, Naito T, Konishi M, Assantachai P, et al. Diagnosis and outcomes of cachexia in Asia: working consensus report from the Asian Working Group for Cachexia. J Cachexia Sarcopenia Muscle. 2023;14:1949\u201358. https:\/\/doi.org\/10.1002\/jcsm.13323.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1591_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2024-004820","author":"K Amano","year":"2024","unstructured":"Amano K, Okamura S, Baracos V, Mori N, Sakaguchi T, Uneno Y, et al. Fluid retention and weight loss in refractory cancer cachexia. BMJ Support Palliat Care. 2024. https:\/\/doi.org\/10.1136\/spcare-2024-004820.","journal-title":"BMJ Support Palliat Care"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01591-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01591-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01591-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:01:45Z","timestamp":1789167705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01591-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01591-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Gifu University Graduate School of Medicine (approval number 2024\u2009\u2212\u2009314) and was conducted in accordance with the Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because of the retrospective nature of this study, the requirement for informed consent was waived by the Ethics Committee of Gifu University Graduate School of Medicine.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Fujii has received honoraria for lectures from Daiichi Sankyo, Kyowa Kirin, Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. H Iihara has received honoraria for lectures from Astellas Pharma Co., Ltd., AstraZeneca plc, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly and Company, Nippon Kayaku Co., Ltd., Ohara Pharmaceutical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd.; and consulting fees from Astellas Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd.R Kobayashi has received honoraria for lectures from TEIJIN Pharma, Astellas Pharma, Janssen Pharmaceutical K.K.A Suzuki has received honoraria for lectures from Toa Eiyo, Asahi Kasei Pharma, Daiichi Sankyo, Pfizer, Eisai, Nippon Shinyaku, Kyowa Kirin, Tsumura, Towa Pharmaceutical, Nippon Kayaku, Mochida Pharmaceutical, EA Pharma, Yakult Honsha, Chugai Pharmaceutical; grants made to institution from Nippon Kayaku, Asahi Kasei Pharma, Chugai Pharm., Taiho Pharm., Daiichi Sankyo, Japan Blood Products Organization, Mochida Pharm., Sun Pharma.N Matsuhashi has received honoraria for lectures from Abbott, Alfresa Pharma, AMCO Inc., Asahi Kasei Pharma, AstraZeneca, Bayer Yakuhin, Bristol-Myers Squibb, Chugai Pharm., Covidien Japan, Daiichi Sankyo, EA Pharma, Eisai, Eli Lilly Japan, Guardant Health Japan Corp, Gunze Medical Limited, Intuitive Surgical, Johnson & Johnson, Kaken Pharm., Kyowa Kirin, MC Medical, Merck Biopharma Japan, Miyarisan Pharm., MSD, Novartis, Olympus Marketing, Inc., Ono Pharm., Stryker, Taiho Pharm., TAKATA Pharm., Takeda Pharm., TERUMO, Tsumura, Viatris, Yakult Honsha, ZERIA Pharm.; grants made to institution from Asahi Kasei Pharma, Chugai Pharm., Covidien Japan, Daiichi Sankyo, Eisai, Eli Lilly Japan, EP\u2010CRSU, EPS Corporation, Johnson & Johnson, Kaken Pharm., Kyowa Kirin, MSD, Nippon Kayaku, Ono Pharm.\u00b8 Otsuka Pharm., ShiftZero K.K., Taiho Pharm., Toray Medical, Tsumura.The other authors have no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"218"}}